The Invesco Biotechnology & Genome ETF (PBE), a passively managed ETF with $218.91 million in assets, seeks to mirror the Dynamic Biotechnology & Genome Intellidex Index. PBE's largest holding is Natera Inc (5.34%), and the fund has a concentrated portfolio of 32 holdings with 99.8% allocated to healthcare; it has underperformed this year, down 7.16% YTD and 3.12% over the last year, with a relatively high risk profile (beta of 0.79 and standard deviation of 22.19%).
The Invesco Biotechnology & Genome ETF (PBE), a passively managed fund with $218.91 million in assets, provides exposure to the Healthcare - Biotech segment by tracking the Dynamic Biotechnology & Genome Intellidex Index, which evaluates companies based on criteria including price and earnings momentum, quality, management action, and value. The ETF maintains a highly concentrated portfolio with approximately 32 holdings, where 99.80% of assets are allocated to the healthcare sector and the top 10 holdings account for 45.87% of total assets, with Natera Inc. (NTRA) being the largest at 5.34%. Despite the Healthcare - Biotech sector's ranking in the top 25% by Zacks, PBE has demonstrated recent underperformance, with a year-to-date loss of 7.16% and a 3.12% decline over the past year as of May 27, 2025. The fund's annual operating expense ratio is 0.58%, on par with peers, and it offers a minimal 12-month trailing dividend yield of 0.07%. PBE carries a Zacks ETF Rank of 3 (Hold) and is characterized by a high-risk profile, indicated by a beta of 0.79 and a standard deviation of 22.19% over the trailing three-year period, alongside a more concentrated exposure compared to some alternatives.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
